MLNT CFO sells shares, reducing direct holdings

What happened: On May 14, 2026, Remitly's CFO, Ankur Sinha, sold 50,000 shares, valued at approximately $1.17 million. On June 22, MoonLake Immunotherapeutics' CFO, Bodenstedt, sold 39,120 shares. On May 11, 2026, Bodenstedt sold another 13,653 shares.

Market impact: These transactions reduced the CFOs' direct holdings by 3.83% and 3.4% respectively, signaling a potential shift in their investment strategies. However, the sales were relatively small portions of their overall holdings, suggesting they remain confident in the companies' long-term prospects.

What to watch next: MoonLake Immunotherapeutics' upcoming earnings report on July 28, 2026, will provide insight into the company's financial health and Bodenstedt's confidence in its future. Additionally, any further insider trading activity by either CFO will offer more clarity on their investment strategies.